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Abstract
We previously reported the development of a lethal myeloid sarcoma in a non-human primate model utilizing retroviral
vectors to genetically modify hematopoietic stem and progenitor cells. This leukemia was characterized by insertion of the
vector provirus into the BCL2A1 gene, with resultant BCL2A1 over-expression. There is little information on the role of this
anti-apoptotic member of the BCL2 family in hematopoiesis or leukemia induction. Therefore we studied the impact of
Bcl2a1a lentiviral over-expression on murine hematopoietic stem and progenitor cells. We demonstrated the anti-apoptotic
function of this protein in hematopoietic cells, but did not detect any impact of Bcl2a1a on in vitro cell growth or cell cycle
kinetics. In vivo, we showed a higher propensity of HSCs over-expressing Bcl2a1a to engraft and contribute to
hematopoiesis. Mice over-expressing Bcl2a1a in the hematologic compartment eventually developed an aggressive
malignant disease characterized as a leukemia/lymphoma of B-cell origin. Secondary transplants carried out to investigate
the primitive origin of the disease revealed the leukemia was transplantable. Thus, Bcl2a1 should be considered as a proto-
oncogene with a potential role in both lymphoid and myeloid leukemogenesis, and a concerning site for insertional
activation by integrating retroviral vectors utilized in hematopoietic stem cell gene therapy.
Citation: Me´tais J-Y, Winkler T, Geyer JT, Calado RT, Aplan PD, et al. (2012) BCL2A1a Over-Expression in Murine Hematopoietic Stem and Progenitor Cells
Decreases Apoptosis and Results in Hematopoietic Transformation. PLoS ONE 7(10): e48267. doi:10.1371/journal.pone.0048267
Editor: Kevin D. Bunting, Emory University, United States of America
Received May 8, 2012; Accepted September 21, 2012; Published October 30, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by the intramural research programs of the National Heart Lung and Blood Institute (CED) of the National Institutes of Health.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dunbarc@nhlbi.nih.gov
. These authors contributed equally to this work.
Introduction
Recently we reported the development of an acute myeloid
leukemia in a rhesus macaque transplanted with autologous
CD34+ cells transduced with a murine stem cell virus-derived
replication defective retroviral vector expressing only marker
genes under control of the strong MCSV long terminal repeat
(LTR). This animal had an unusual clonal reconstitution pattern
the first year following transplant, with a single transduced
myeloid progenitor cell clone accounting for up to 80% of the
then normal myelopoiesis [1]. The same vector-containing clone
eventually transformed to AML five years following transplan-
tation, and each tumor cell was shown to contain two vector
insertions, one localized 20 kb upstream of the CDw92 gene on
chromosome 9, and the second localized in the first intron of
BCL2A1 on chromosome 15 [2], a gene belonging to the anti-
apoptotic BCL2 family not previously linked to myeloid
leukemia. BCL2A1 was highly expressed in the tumor cells.
This tumor was the first hematopoietic malignancy reported in
a recipient of primitive cells transduced with a replication-
incompetent vector containing only marker genes, and suggested
that BCL2A1 could have potent effects on hematopoiesis.
BCL2A1, also known as Bfl-1, GRS, or BCL2L5, belongs to the
BCL2 family of anti-apoptotic proteins. Murine BCL2A1 was
originally identified as a gene product induced by the stimulation
of primary bone marrow cells with GM-CSF [3]. The human
homolog was later cloned in three independent studies [4–6].
Initially its expression was thought to be specific to the
hematopoietic compartment [7], but further studies showed a less
restrictive expression pattern [5]. For instance, expression of
Bcl2a1 starts at day E11.5 in brain, limbs, and liver during mouse
embryogenesis. At day E15.5 it is also detected in yolk sac, heart,
thymus, lung, kidney, and spleen [8]. In mice the Bcl2a1 gene is
duplicated, giving rise to 4 variants named Bcl2a1a, b, c, and d [9].
This phenomenon is not shared by other species even though 2
splice variants with the same function were described in humans
[10].
Bcl2a1a knock-out in C57BL/6 mice is not lethal, and mice
have a normal lifespan. However, neutrophils of Bcl2a1a-deficient
mice are more prone to apoptosis, suggesting an anti-apoptotic
function for this protein [11]. A recent study used RNAi to down-
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regulate all of the murine isoforms of Bcl2a1, and demonstrated
diverse actions of this gene product in the development and
homeostasis of T cells, B cells and granulocytes [12]. During
normal myeloid maturation, neutrophilic differentiation is linked
to up-regulation of BCL2A1, in part via activation of the BCL2A1
promoter by the transcription factor PU.1 [13]. In myeloid
leukemias, PU.1 and BCL2A1 expression are highly correlated
[13]. Expression of BCL2A1 can be induced by various molecules
such as tumor necrosis factor a (TNFa), phorbol 12-myristate 13-
acetate (PMA), lipopolysaccharide (LPS), or interleukin-1 (IL-1)
(e.g.: [14], [15], [5]). NFKB directly regulates the expression of
BCL2A1 and recruits a large transcriptional complex at its
promoter [16–18]. Most anti-apoptotic proteins, when over-
expressed or deregulated, act to induce or accelerate hematologic
malignancies, often by potently interacting with mutations in
proliferative pathways such as deregulating of MYC, or interfering
with p53 death signals [19–21]. The first member of this class,
BCL2, was discovered as the gene activated by a chromosomal
translocation in virtually all cases of human follicular lymphoma
[22].
There is limited information linking BCL2A1 expression and
human hematologic malignancies. In one small study BCL2A1
mRNA was over-expressed in acute lymphoid leukemia (ALL),
acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL),
chronic myeloid leukemia (CML), and mantle cell lymphoma
tumor cells compared to normal marrow cells [23]. Levels were
particularly elevated in AML patients with a normal karyotype.
However, the potential role of BCL2A1 as a marker for subtypes
of AML needs further study [23]. In a murine model, similar to
other anti-apoptotic proteins, BCL2A1 expression has recently
been shown to accelerate the onset of myeloid leukemia induced
by MYC over-expression. Other anti-apoptotic BCL2-family
genes were also tested (BCL2, BCLxL, BCLw, MCL1, and BCLb)
in this model, and BCL2A1 was the least potent cooperative gene
with MYC in AML induction [24]. However, the impact of
BCL2A1 expression alone was not studied in this set of
experiments.
In this study we aimed to better understand the potential role of
dysregulation of the Bcl2a1a gene in etiology of leukemia. We
hypothesized that over-expression of Bcl2a1a would confer a
selective advantage to the cells through its anti-apoptotic function,
facilitating eventual development of leukemia. Hence, we over-
expressed Bcl2a1a in the hematologic compartment in a murine
model, in order to study its impact on hematopoiesis and the
possible emergence of malignant disease.
Materials and Methods
Ethics Statement and Animal Care
All mice were housed and handled in strict accordance with the
recommendations in the ‘‘Guide for the Care and Use of
Laboratory Animals’’ of the National Institutes of Health,
Bethesda, MD. All animal experiments were carried out on
National Heart Lung and Blood Institute Animal Care and Use
Committee–approved protocol number H-1031R2.
Vector Construction and Production
Murine Bcl2a1a cDNA was cloned from total RNA extracted
from C57BL/6 mouse heart using the Qiagen RNEasy mini kit
(Qiagen, Hilden, Germany), following first strand cDNA synthesis
via the Superscript First Strand kit (InvitrogenTM, Life Technol-
ogies, Carlsbad, CA). Primers mBCL2A1AFOR(1-21) 59-
ATGGCTGAGTCTGAGCTCATG-39 and
mBCL2A1AREV(519-498) 59-TTACTTGAGGAGAAAGAG-
CAT-39 were used to amplify the open reading frame of the gene
and the PCR product was subcloned into the pCR4TOPO vector
(InvitrogenTM, Life Technologies). The human BCL2A1 gene was
purchased from B-Bridge International (Clone IR-
ATp970D1012D, Cupertino, CA). After amplification by PCR
with primers introducing a Kozak sequence as well as restriction
enzyme sites, the genes were subcloned into the pMIEV-IRES-
GFP retroviral vector. An HA tag was also added to pMIEV-
IRES-GFP vectors with the Stratagene Quick Change II site
directed mutagenesis kit (Agilent Technologies, La Jolla, CA). The
HA-tagged murine Bcl2a1a and human BCL2A1 sequences were
introduced into the pRRL.PPT.SF.GFPpre lentiviral vector along
with the IRES sequence [25]. Vectors utilized in these studies are
summarized in Figure 1A.
To produce lentiviral particles, 293T cells were seeded at 5
million cells per 10-centimeter dish. Twenty-four hours later, cells
were co-transfected (Calcium Phosphate Transfection Kit, Sigma-
Aldrich, Saint Louis, MO) with the following plasmids: pCDNA3.-
HIVgag/pol.4xCTE (12 ug), pMD2.G-VSV-G (1 ug), pRSV-
REV (5 ug), and 10 ug of pRRL.PPT.SF.IRES.GFPpre/HA,
pRRL.PPT.SF.IRES.GFPpre/HA-mBcl2a1a, or
pRRL.PPT.SF.IRES.GFPpre/HA-hBCL2A1. Vector-superna-
tants were collected once a day for 3 days, filtered through 0.22-
um filters, and concentrated by ultracentrifugation for 2 hr at 71
900 g and 4uC in a SW28 rotor (Beckman Coulter, Atlanta GA).
Pelleted viral particles were resuspended in 1 mL of StemSpanH
(StemCell Technologies Inc., Vancouver, Canada) media and
stored at minus 80uC. Viral titers were determined on NIH 3T3
cells via standard assays [26].
Cell Culture and Transduction
The murine myelomonocytic WEHI-3 (ATCC, #TIB-68,
Manassas, VA) cell line was grown in IMDM supplemented with
10% FCS, 2.5 mM b2-mercapto-ethanol, glutamine, penicillin
and streptomycin. Murine NIH3T3 (ATCC, #CRL-1658) and
human 293T (ATCC, #CRL-11268) fibroblastic cell lines were
grown in I10 media (IMDM supplemented with 10% FCS,
glutamine, penicillin and streptomycin). The murine pro-B BaF3
(Leibniz-Institut DSMZ, #ACC300, Braunschweig, Germany)
and murine myeloblast-like 32Dcl3 (ATCC, #CRL-11346) cell
lines were grown in RPMI1640X supplemented with 10% WEHI-
3 conditioned media as a source of IL-3, 10% fetal calf serum
(FCS Heat-inactivated, Sigma-Aldrich), glutamine, penicillin and
streptomycin (Gibco, Life Technologies, Grand Island, NY). The
human erythroblastoid UT7/Epo-S1 cell line was grown in I10
media containing 2 U/mL of human erythropoietin (Amgen,
Thousand Oaks, CA). Fifty thousand BaF3, 32Dcl3, or UT7/Epo-
S1 cells [27] were transduced with vector particles on retronectin-
coated plates (Takara, Madison, WI) at a multiplicity of infection
(MOI) of 5 in presence of protamine sulfate 4 ug/mL (Sigma-
Aldrich).
Murine bone marrow cells were obtained by flushing bone
marrow from humeri, femurs, and tibias of C57BL/6 Ly5.1
mice (C57BL/6 Ly5.1 (Pep3b) Stock 002014, Jackson Labora-
tories, Bar Harbor, ME). Red cells were lysed with ACK buffer
(Quality Biological Inc., Gaithersburg, MD). Nucleated cells
were purified using the MACS mouse lineage depletion kit
(Miltenyi Biotec, Auburn, CA), and the resulting lineage
negative progenitor cells were stimulated for two days at a
starting density of 56105 cells/mL in StemSpanH media
supplemented with 10 ng/mL murine IL-3 (R&D Systems,
Minneapolis, MN), 100 ng/mL murine IL-11 (R&D Systems),
50 ng/mL murine stem cell factor (Research Diagnostic Inc.,
Concord, MA), and 100 ng/mL human Flt-3 Ligand (R&D
BCL2A1a as a Survival Factor
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Systems). Each recipient mouse was transplanted with the
equivalent of 56105 stimulated cells that were transduced twice
with lentiviral supernatants at a MOI of 5 on retronectin-coated
plates in the presence of protamine sulfate 4 ug/mL.
Murine Transplantation and Follow-up
Transduced lineage negative bone marrow cells were resus-
pended in StemSpanH media. Following 900 rads total body
irradiation each recipient C57BL/6 Ly5.2 mouse (Stock 000664,
Jackson Laboratories) received transduced cells resuspended in
500 uL media via tail vein injection.
To perform secondary transplants, bone marrow cells were
collected by flushing humeri, femurs, and tibias of primary mice,
and red cells were lysed using ACK buffer. Using a ratio of 1
primary mouse for 3 secondary mice, primary bone marrow cells
were reinfused by tail vein injection into sub-lethally irradiated
secondary mice C57BL/6 (Ly5.2) (900 rads total body irradiation).
Blood was collected monthly via retro-orbital bleeding, and used
for a complete blood count (Hemavet 950FS, Drew Scientific,
Waterbury, CT), blood smear (hematoxylin and eosin (H&E)
stained), and flow cytometric analysis.
Organs including heart, lung, kidney, spleen, liver, salivary
glands, lymph nodes, any obvious tumor masses, and sternum
from pre-morbid mice were collected, fixed in 10% formalin
(Fischer Scientific, Thermo Fisher Scientific Inc., Pittsburgh, PA),
and embedded into paraffin blocks for subsequent sectioning and
H&E staining (Histosev, Gaithersburg, MD) or immunohisto-
chemistry. Single cell bone marrow, lymph node, and spleen
suspensions were obtained by flushing tissues with media.
Cytospins were prepared from 105 cells, using 300 rpm for 5
minutes (CytoSpin 4 Cytocentrifuge, Thermo Scientific, Thermo
Fisher Scientific Inc.). Cell suspensions were analyzed by flow
cytometry. Genomic DNA was isolated from cells or tissues using
Qiagen DNeasy Tissue and Blood kit according to manufacturer’s
recommendation.
Flow Cytometric Analysis and Cell Sorting
Transduced BaF3, 32Dcl3, and UT7/Epo-S1 cells were sorted
for GFP expression using a BD FACSAria cell sorter from BD
Bioscience (San Jose, CA). Peripheral blood, bone marrow, and
spleen cells were resuspended in FACS buffer (2.7 mM Potassium
chloride, 1.5 mM Sodium phosphate dibasic heptahydrate,
1.5 mM Potassium phosphate monobasic, Sodium chloride
137 mM, Sodium azide 7.7 mM, 1% (w/v) BSA in water) and
incubated with the following cocktail of antibodies from BD
PharmingenTM (BD Bioscience, San Diego, CA): T-cells-anti-
mouse CD3e (Hamster, APC), granulocytes and NK cells-anti-
mouse CD11b (Rat, PE-Cy7), B-cells-anti-mouse CD45R/B220
(Rat, APC-Cy7). Engraftment of donor cells was monitored via
anti-mouse CD45.1 (Mouse, R-PE) and anti-mouse CD45.2
(Mouse, PerCP-Cy5.5). After washing with FACS buffer, cells
were analyzed with a BDTM LsrII flow cytometry system from BD
Bioscience. Data were analyzed using FlowJo from Treestar Inc.,
Ashland, OR).
Figure 1. Construction of BCL2A1 lentiviral vectors, and demonstration of high level expression in producer and transduced cell
line.(A) Schematic of the lentiviral vectors used for expression of murine BCL2A1a or human BCL2A1. LTRs are self inactivating (SIN), y
(packaging sequence), RRE (Rev-Responsive Element), PPT (Polypurine Tract), SFFV (Spleen Focus-Forming Virus promoter), IRES (Internal Ribosome
Entry Site), HA (Hemagglutinine antigen), GFP (Green Fluorescent protein), PRE (post-transcriptional regulatory element). (B,C) Expression was
assessed by western blot using an anti-HA antibody to recognize HA-tagged BCL2A1, or anti-GFP, and anti GAPDH as a loading control. Western blots
were carried out in 293T producer cell lines (B) and in transduced BAF3 and 32Dcl3 cells (C).
doi:10.1371/journal.pone.0048267.g001
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Cell Cycle and Apoptosis Assays
Cell cycle status was assessed using the NuCyclTM PI Kit from
Exalpha (Watertown, MA) according to the manufacturer’s
recommendation. Apoptosis was assessed using the Annexin V-
PE apoptosis detection kit I from (BD PharmingenTM, BD
Biosciences). Analysis of cell cycle and apoptosis was performed
on a BDTM LsrII flow cytometer. Data were processed using
ModFitTM software from Verity Software House (Topsham, ME).
Immunohistochemistry
Immunohistochemical staining was performed on formalin-
fixed, paraffin-embedded tissue sections from the spleen, liver,
sternal bone marrow, affected lymph nodes, and tumor masses.
Cut tissue sections were deparaffinized, and endogenous
peroxidase was inactivated. Antibodies included rat anti-mouse
B220 (clone RA3-6B2, BD PharmingenTM, BD Biosciences),
rabbit polyclonal anti-mouse CD3 (Dako, Glostrup, Denmark),
rat anti-mouse CD34 (Clone MEC 14.7, Abcam, Cambridge,
MA), rat anti-mouse CD68 (Clone FA-11, Abcam), mouse anti-
mouse Lysozyme (clone BGN/06/961, Abcam), rat anti-mouse
Mac2 (Clone M3/38, Cedarlane Laboratories Limited, Burling-
ton, NC), rabbit anti-human myeloperoxidase (MPO) with cross-
reactivity to mouse (Dako), peanut agglutinin (Vector Labora-
tories, Burlingame, CA), and rabbit anti-human TdT with cross-
reactivity to mouse (Supertechs Inc., Rockville MD). For CD3,
CD34, lysozyme, Mac2 and MPO staining, antigen retrieval
was performed using either the Bond Epitope Retrieval Solution
1 (ER1) or the Bond Epitope Retrieval Solution 2 (ER2) (Leica
Biosystems, Newcastle Upon Tyne, UK) at 99–100uC for 20–
30 min. Enzymatic retrieval was performed for CD68. TdT was
kept in a pressure cooker in citrate buffer with pH=6 for 10
minutes. Subsequently, CD3, MPO, and TdT sections were
incubated with the primary antibody for 30 minutes, followed
by incubation with enVision + System HRP labeled polymer
anti-rabbit secondary antibody (Dako) for 25 minutes. Antibod-
ies for B220, CD34 and Mac2 were incubated with the primary
antibody for 30 minutes, followed by a secondary biotinylated
polyclonal goat anti-rat antibody (BD PharmingenTM, BD
Biosciences) for 25 minutes and Streptavidin-HRP (Dako) for
25 minutes. Lysozyme was stained using the Animal Research
Kit Peroxidase for mouse primary antibodies (Dako), as
described by the manufacturer. Sections underwent colorimetric
development with diaminobenzidine (DAB, Leica Biosystems),
were counterstained with hematoxylin, dehydrated using graded
alcohols and mounted in CytosealTM XYL (Richard-Allan
Scientific, Kalamazoo, MI).
Western Blot
Frozen spleen fragments were ground in a total volume of
750 uL of RIPA buffer (Sigma-Aldrich) supplemented with a
cocktail of protease inhibitors (Complete Mini EDTA-Free and
PhosSTOP, Roche, Indianapolis, IN). After clarification by
centrifugation for 20 min at 20 800 g and 4uC, protein
concentration was determined using the Protein Assay reagent
(Bio-Rad, Hercules, CA). Proteins from 14 ug of lysate were
separated by electrophoresis on 4–15% acrylamide Ready gel
(Biorad) in Tris/Glycine/SDS buffer (Bio-Rad). Protein stan-
dards BenchMarkTM and MagicMark (InvitrogenTM, Life
Technologies) were used as recommended by manufacturer.
Proteins were transferred to nitrocellulose membranes (Nitrocel-
lulose Membrane Filter Paper Sandwich, InvitrogenTM, Life
Technologies) for 1 hr at 90 V in 10% methanol Tris/Glycine
buffer (Bio-Rad). Membranes were rinsed in water, and blocked
in 5% milk (Bio-Rad)/0.05% Tween20 (Bio-Rad)/PBS, pH 7.4
for 1 hr at room temperature. Primary mouse monoclonal
antibodies including anti-HA (Clone 16B12, Covance, Berkeley,
CA), anti-GAPDH (Clone 6C5, Ambion, Austin, TX), or anti-
GFP (Clone 7.1 and 13.1, Roche) were diluted in 5% milk/
0.05% Tween/PBS and incubated at 4uC overnight. Mem-
branes were washed twice in 0.05% Tween/PBS for 10 min at
room temperature. Secondary anti-mouse immunoglobulins/
HRP polyclonal antibody (Dako) conjugated to HRP was
diluted in 5% milk/0.05% Tween/PBS and incubated at room
temperature for 45 min. After washing three times with 0.05%
Tween/PBS and once with PBS, the membrane was incubated
with electrochemiluminescent substrate (LumiGLOR, Cell Sig-
naling Technology, Danvers, MA). Membranes were then
exposed to a Luminescent Image Analyser (LAS-400, Fujifilm,
Tokyo, Japan).
Real-time PCR
Total RNA was isolated using RNeasy mini kit according to
manufacturer’s instruction (Qiagen). DNAse I (RNAse-free DNAse
set, Qiagen) was added to remove any residual contaminating
genomic DNA. Real-time PCR was carried out on 75 ng of total
RNA per sample using the TaqManH One-Step RT-PCR Master
Mix Reagents Kit (Applied Biosystems, Foster City, CA) according to
manufacturer’s instruction. Primers and probes designed to detect
total murine Bcl2a1a and b2-Microglobulinwere as follows: FOR-mb2-
Microglobulin 59-CTTCAGCAAGGACTGGTCTTTC-39; REV-
mb2-Microglobulin 59-CGGCCATACTGGCATGCTTAAC-39;
Probe-mb2-Microglobulin 59FAM-TGAATTCACCCCCACTGA-
GACTG-39TAMRA; FOR-mBCL2A1a 59-GATACGGCAGA-
ATGGAGGTT-39; REV-mBCL2A1a 59-GCATTTCCCAGA-
TCTGTCCT-39; Probe-mBCL2A1a 59FAM-TGAACCCAAATC-
TGGCTGGCTG-39TAMRA. Reactions were carried out in
triplicates for each sample on an ABI PRISM 7900HT Sequence
Detection System from Applied Biosystems. Copy numbers were
calculated based on standard curves using plasmids harboring
Bcl2a1a and b2-Microglobulin genes.
PCRs for Immunoglobulin Variable Heavy Chain
Rearrangements
An adaptation of the PCR-based method reported by
Schlissel and colleagues was used [28], with MuO, VH558,
VH7183, DHL, and DHR as forward primers and either J3 or
J4 as reverse primers. PCRs were performed with 100 ng of
genomic DNA, 16 uL of Platinum PCR SuperMix High Fidelity
(InvitrogenTM, Life Technologies), and 1 uL of each forward
and reverse primer resuspended at 10 uM. We performed an
initial denaturation step of 4 min at 94uC followed by 32 cycles
of 1 min at 94uC, 1 min at 60uC, 1.75 min at 72uC, to end by
a final extension of 10 min at 72uC. PCRs were loaded on 2%
agarose gel in tris-acetate buffer.
Southern Blot
Genomic DNA was digested overnight with HindIII/Sac1
(TCR) or PciI (GFP) and separated on a 0.8% agarose (Ultrapure
Agarose, InvitrogenTM, Life Technologies) gel and transferred
overnight to a nylon membrane (Amersham HybondTM-XL, GE
Healthcare, Buckinghamshire, UK). The TCRb probe was
obtained by digesting pBR322/TCRb2 by BglII and the GFP
probe was obtained by PCR performed on pRRL.PPT.SF.IR-
ES.GFPpre/HA plasmid with SB-GFP-FOR 59-GGCCA-
CAAGTTCAGCGTGTC-39 and SB-GFP-REV 59-
AGCTCGTCCATGCCGAGAGT-39 primers. Probes were ra-
diolabeled using a labeling Kit (Amersham Ready-To-Go DNA
BCL2A1a as a Survival Factor
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Labeling Beads (-dCTP), GE Healthcare) with radioactive
phosphate (EasyTides Deoxycytidine 59 triphosphate [a32-P],
Perkin Elmer, Boston, MA).
Statistical Analyses
Kaplan–Meier survival curves (overall survival and disease-
free survival) were established using Prism 4 from GraphPad
Software (La Jolla, CA). This software was also used for other
statistical analyses. One-way ANOVA was used to compare
more than 2 data sets. Two-way ANOVA was used to compare
more than 2 data sets over time. Student t-test was used to
compare 2 data sets.
Results
BCL2A1 is Efficiently Over-expressed in Transduced Cells
We chose to utilize lentiviral vectors to over-express BCL2A1,
given their more robust expression levels, higher titers, and
marked decrease in insertional mutagenesis as compared to
standard retrovirus vectors [29]. Vector particles pseudotyped
with the VSV-G envelope were produced via transient transfection
of 293T cells, concentrated, titered and used to transduce several
cytokine-dependent hematopoietic cell lines, including BaF3,
32DCl3, and UT7/Epo-S1. We documented expression of HA-
tagged murine BCL2A1a and human BCL2A1 in both 293T
producer cells and in transduced BaF3 and 32DCl3 cells by
western blot, as shown in Figure 1B and 1C.
BCL2A1 is Anti-apoptotic in Hematopoietic Cells but
does not have an Impact on Cell Growth or Cell Cycle
BaF3 and 32Dcl3 cells are dependent on IL-3, and UT7/Epo-
S1 cells are dependent on erythropoietin. When these cells are
deprived of cytokines they undergo rapid apoptosis. The over-
expression of murine HA-BCL2A1a or human HA-BCL2A1 did
not alter the growth of BaF3 cells in the presence of IL-3
(Figure 2A). However, when deprived of IL-3, BaF3 cells over-
expressing murine HA-BCL2A1a or human HA-BCL2A1 re-
mained significantly more viable compared to cells transduced
with a vector expressing GFP alone or control untransduced cells
(MOCK) (Figure 2A).
We assessed the cell cycle status of transduced cells grown in the
presence or absence of IL-3. No obvious difference in cell cycle
characteristics was seen in the presence of IL-3 (data not shown).
However, 1 day after IL-3 deprivation a sub-G1 population
appeared. As shown in Figure 2B, the percentage of sub-G1 cells
was significantly reduced in BaF3 cells over-expressing murine
BCL2A1a or human BCL2A1 (20% and 5%, respectively) when
compared with control cells (MOCK and vector both 45%). Sub-
G1 cells are usually associated with apoptosis, hence we directly
assessed the apoptotic status of these cells.
Cells over-expressing murine BCL2A1a or human BCL2A1
were protected against apoptosis compared to MOCK or control
GFP vector-transduced cells following IL-3 deprivation. Two days
following removal of IL-3, almost all MOCK and vector control
cells were apoptotic, compared to 50% and 20% for murine HA-
BCL2A1a and human HA-BCL2A1 (p,0.0001) (Figure 2C).
Similar results were obtained in transduced murine 32Dcl3 cells
deprived of IL-3, or human UT7 UT7/Epo-S1 cells deprived of
erythropoietin (data not shown). These results confirm the anti-
apoptotic function of BCL2A1 over-expressed in hematopoietic
cells using lentiviral vectors.
BCL2A1a Over-expression Increases the Engraftment of
Hematopoietic Stem Cells
We studied the impact of over-expression of murine BCL2A1a
on the behavior of primary hematopoietic stem and progenitor
cells using a murine congenic transplantation model. Bone
marrow cells from Ly5.1 C57BL/6 mice were transduced with
lentiviruses expressing GFP alone or GFP/HA-BCL2A1a prior to
reinfusion into sublethally-irradiated Ly5.2 C57BL/6 recipient
mice. Five mice received untransduced donor cells, 15 mice
received GFP-vector transduced cells, and 15 received GFP-
murine BCL2A1a-vector transduced donor cells. From the donor
cells kept in vitro we determined the fold increase expression at the
mRNA level of Bcl2a1a to be 5 compared to controls (MOCK and
Vector) after 5 or 10 days post-transduction (Figure 3A). The set of
primers did not discriminate between endogenous and exogenous
murine Bcl2a1a, but primers designed to detect the HA-tag only
showed expression of exogenous Bcl2a1a in cells transduced with
the HA-Bcl2a1a construct (data not shown). Mice receiving bone
marrow cells over-expressing HA-BCL2A1a had significantly
better engraftment than mice receiving MOCK or vector control
cells (p,0.0001) (Figure 3B). The level of peripheral blood cells
expressing GFP was also higher in the Bcl2A1a-GFP versus GFP
alone recipients, 80% versus 10% respectively. We confirmed the
in vivo expression of HA-BCL2A1a in primary hematopoietic cells
by western blot of the spleen, as shown in Figure 3C.
Mice Over-expressing BCL2A1a Develop Aberrant
Hematopoiesis, Organomegaly and Tumor Masses
Up to six months following transplantation, all mice remained
healthy and with normal blood counts. However, following this
time point, mice in the BCL2A1a cohort began to show symptoms
of a systemic disease with weight loss, hunching, and lack of
grooming, and consequently had to be euthanized. Peripheral
blood counts were still in the normal range at that time
(Supplemental Figure S1A, S1B, and S1C). At postmortem,
affected BCL2A1a mice, compared to GFP mice, had enlarged
spleens and livers, as well as large inguinal and axillary lymph
nodes (Supplemental Figure S2). In histopathological analyses
multiple tissues were infiltrated with large immature blasts with a
high nuclear to cytoplasmic ratio (Figure 4A). The normal
architecture of bone marrow, spleen, and lymph nodes was
completely effaced by these abnormal cells (Figure 4A and B).
These abnormal cell populations were not seen in MOCK and
vector control mice. The abnormal cells were GFP positive. Only
mice receiving cells transduced with the BCL2A1a construct
developed the malignant disease as shown in overall and disease-
free survival analyses (Figure 5A and B). We did not observe this
type of malignant phenotype in the GFP vector or MOCK mice
(Figure 5B).
We further characterized the blast cells infiltrating tissues in
BCL2A1a mice, because they were not consistently positive for
standard lineage markers used for flow cytometric characterization
of murine hematopoietic cells in peripheral blood and bone
marrow (Supplemental Figure S3). Immunohistochemical staining
(Figure 4B) were performed in 8 primary mice: 1 MOCK control
(#3), 1 vector control (#7), and 6 primary BCL2A1a mice (#24,
25, 28, 29, 32, and 33). The 2 control mice and 1 primary
BCL2A1a mouse #24, which was healthy but used for secondary
transplant, had unremarkable morphology and no evidence of
abnormal tissue infiltration as demonstrated by immunohisto-
chemical staining. Three primary mice had morphologic evidence
of an extensively disseminated hematologic malignancy involving
spleen, bone marrow and lymph nodes (#25, 28, and 33). Tumor
BCL2A1a as a Survival Factor
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cells were positive for the B-cell marker B220 and the immature
leukemic marker TdT, and were negative for myeloid and
monocytic markers (MPO, Lysozyme, CD68, Mac2), T-cell
antigen (CD3), and mature germinal center-derived B cell antigen
(peanut agglutinin), consistent with the diagnosis of B-lympho-
blastic leukemia/lymphoma. For 2 primary BCL2A1a mice (#32,
29) the animals showed neoplastic cells positive for TdT but
negative for all other markers, including B220, consistent with the
diagnosis of an acute undifferentiated leukemia.
We analyzed the tumor cells at the molecular level. The
possibility of T cell lineage of the blast cells was ruled out via
Southern blot, which demonstrated germline configuration of the
TCR genes (Figure 6A). The B cell origin of the malignant cells
was confirmed at the molecular level using a PCR-based method
adaptated from Schlissel and colleagues [28]. Bone marrow
infiltrated with tumor from affected mice had clonal V to DJ
rearrangements of the immunoglobulin variable heavy chain gene.
For instance mice#25, 32, and 33 clearly show only one amplicon
when the VH558 and/or VH7183 primer was used with J3 or J4
primers (Figure 6B and C). Control mice represented by MOCK
mouse #3 and vector mouse #7 showed polyclonal populations
comparable to a non transplanted C57BL/6 mouse (M).
(Supplemental Figure S4). Together these results showed that
the malignancy is a lymphoma/leukemia of B-cell origin.
Southern blot performed with a GFP probe on whole bone
marrow cells showed that primary BCL2A1a mice diagnosed with
the lymphoid disease (#25, 26, 28, 32, and 33) did not share the
same profile of integration, suggesting that different infiltrating
clones were responsible for the disease (Figure 6D).
The Malignant Disease is Transplantable
In order to further study the behavior of BCL2A1a-
transduced cells, we performed secondary transplants consisting
of transplanting marrow from primary mice engrafted 6 months
or more with transduced cells into secondary recipients. We
chose a ratio of 1 primary for 3 secondary mice, and reinfused
the cells in this experiment into non-irradiated secondary mice.
All mice receiving cells from BCL2A1a primary mice died
within a month post transplant, with a disease phenotype
similar to the one described above for primary mice (Figure 5C
and 4A). Immunohistochemistry was only positive for the Tdt
marker of blastic cells (data not shown), but the PCR was
positive for B-cell rearrangement using the J4 primer (Figure 6C)
documenting the B-cell origin of the infiltrating cells. Of note,
secondary mice receiving BCL2A1a-transduced primary marrow
developed the phenotype rapidly, even when the primary
donors showed no disease manifestation at the time of
transplant. BCL2A1a secondary mice had leukemic peripheral
blood (Supplemental Figure S1D, S1E, and S1F). There was a
significant difference in the survival of secondary mice receiving
BCL2A1a versus GFP vector primary cells. The mean
Figure 2. Impact of BCL2A1 over-expression in BAF3 cells. (A) Growth curves for BAF3 cells grown with or without murine IL-3. Viable cell
numbers are shown over time. (B) Cell cycle analysis on BAF3 cells grown without IL-3. (C) Apoptosis assessed via Annexin V-PE staining in the
absence of IL-3. All experiments were repeated 3 times and carried out in triplicates. Figure shows results obtained for one representative experiment.
Data averages plus or minus standard deviations were plotted. HA-mBCL2A1a and HA-hBCL2A1 are respectively murine and human HA-BCL2A1.
doi:10.1371/journal.pone.0048267.g002
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engraftment assessed by the presence of Ly5.1 cells in the
peripheral blood was of 84.3% for BCL2A1a secondary mice
whereas for the vector control it was only 2.5%. All the
BCL2A1a secondary mice were diagnosed with the malignant
disease (Figure 5D). Two of the vector control mice established
from the same primary mouse (#20) also developed a
hematologic malignancy late after transplantation, with a
lymphomatous phenotype (Figure 5C and 5D), potentially
related to insertional mutagenesis. For these cases donor cells
(Ly5.1) went up from 1.5% to 74.1% in the peripheral blood at
the time of death with 96% GFP positivity.
In our second attempt secondary mice were sublethally
irradiated at 900 rads. We observed a significant difference in
the overall survival between BCL2A1a and vector control mice
(Figure 5E), however due to a reduced cohort size, the disease-
free survival was not significantly different (Figure 5F). All the
BCL2A1a mice developed a comparable malignant disease.
Southern blot with GFP probe showed different profiles of
integration for BCL2A1a secondary mice from the first cohort
(#29-16, 35-18, 35-19) and the second cohort (23-13) suggesting
different clones responsible for the disease (Figure 6E). We can also
see that infiltrating cells tested from different organs show the same
profile (e.g. 23-13 BM and 23-13 LN) (Figure 6E).
Discussion
We recently reported an adverse event in a monkey treated with
genetically modified stem cells expressing GFP as a marker from a
MSCV-derived retrovirus [2]. After a remarkable in vivo clonal
expansion of the myeloid progeny derived from a single
transduced hematopoietic progenitor with an insertion in the
BCL2A1 locus, accompanied by normal blood counts and myeloid
differentiation early after transplantation, the animal eventually
developed AML derived from the same clone, and died six years
post-transplant [1]. The tumor cells over-expressed BCL2A1
mRNA. Prior to our study, a link between BCL2A1 and AML
has only been suggested [23]. Leukemias and clonal dominance in
both animal models and human gene therapy clinical trials have
been previously linked to insertional activation of LMO2, the
MDS1/EVI1 gene complex, HOXB4, and a number of other
transcription factor genes, but not previously to activation of an
anti-apoptotic gene [30–33].
Figure 3. Expression of Bcl2a1a transgene in murine HSPCs and engraftment in primary recipient mice. (A) Ratio of mRNA expression of
total Bcl2a1a over b2-Microglobulin in transduced lineage negative cells from bone marrow cells 5 or 10 days post-transduction. The MOCK ratio was
set up to 1 and ratios for Vector and HA-mBcl2a1a samples were normalized to MOCK. Primers for Bcl2a1a did not discriminate endogenous and
exogenous mRNAs. (B) Percent engraftment of donor cells (Ly5.1) was assessed in the peripheral blood leukocytes of recipient mice (Ly5.2) one
month post-transplant. (C) Expression of BCL2A1a protein was assessed in the spleens of MOCK mouse #3, vector mouse #7, and BCL2A1a mouse
#25 via western blot. Data averages plus standard deviations were plotted. Antibodies used as for Figure 1.
doi:10.1371/journal.pone.0048267.g003
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To address whether BCL2A1 over-expression can promote
development of leukemia/lymphoma, in the absence of a
specific cooperating oncogene such as MYC, we used a murine
bone marrow transplantation model. We used a lentiviral vector
expressing HA tagged BCL2A1a along with a GFP marker to
over-express this protein in hematopoietic stem and progenitor
cells that were then reinfused into congenic mice. While any
integrating vector can potentially induce leukemia by insertional
mutagenesis alone, the risk is relatively low using lentiviral as
compared to standard murine retroviral vectors, and compar-
ison to the control GFP vector allows analysis of the impact of
BCL2A1a over-expression independent of any vector effects
Figure 4. Analyses of bone marrow cells by microscopy after H&E staining and immunohistochemistry of tumor cells. (A) Micrographs
obtained from H&E stained slides of sternal sections or cytospins from bone marrow cells. Primary BCL2A1a mice #25 and #33 as well as secondary
mouse #24-12 are represented. Sternal sections were appreciated at 20X magnification whereas blastic cells from cytospins were appreciated at
100X magnification. (B) Example of immunohistochemical staining of lymph nodes from primary BCL2A1a mouse (#33). Lymph node sections were
stained with antibodies directed against antigens including B220 for B-cells, CD3 for T-cells, TdT for immature leukemic cells, lysozyme for myeloid
cells, CD68 for monocytes or histiocytes. Sections were also stained with Hematoxylin and Eosin (H&E).
doi:10.1371/journal.pone.0048267.g004
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[34]. Analysis of insertion sites from the bone marrow of two
BCL2A1a mice (primary #25 and secondary #23-11) with
tumors, and one vector control mouse without tumor (primary
#7) did not reveal vector insertions within or adjacent to proto-
oncogenes such as Myc. None of the insertion sites were shared
between independent tumors (Supplementary Table S1). We
confirmed that murine BCL2A1a and human BCL2A1 over-
expressed via this lentiviral vector could protect several
hematopoietic cell lines from apoptosis in vitro. Following
transplantation, murine marrow cells transduced with the
BCL2A1a vector demonstrated higher engraftment levels
compared to cells transduced with the control vector, possibly
resulting from the anti-apoptotic function of BCL2A1a, allowing
better survival of successfully-transduced cells in vitro during
culture, and in vivo during the process of homing and
engraftment. For the first six months, hematopoiesis in these
mice appeared normal and was analogous to the initial clonal
dominance with normal hematopoiesis observed in our primate
model when the BCL2A1 gene was activated by vector insertion
[1]. With longer follow-up, we found that BCL2A1a over-
expression resulted in a malignant hematologic disease with
prolonged latency.
Our previous study [2] and the study from Beverly and Varmus
[24], led us to hypothesize that BCL2A1a would induce a myeloid
leukemia. However, we characterized the malignant tumors in
individual mice as lymphoblastic leukemias/lymphomas of the B-
cell lineage. The discrepancy between our findings and the
previous murine study [24] can be explained by the fact that in
their experiments BCL2A1 was over-expressed along with MYC,
whereas we over-expressed BCL2A1a alone. It has been estab-
lished that MYC alone induces a myeloid leukemia [35], and the
co-expression of high levels of all anti-apoptotic proteins in their
model simply accelerated the time to presentation of the myeloid
leukemia phenotype. Even oncogenes with a very clear link to
primarily myeloid malignancies in humans, such as BCR-ABL, can
result primarily in a lymphoid malignant phenotype when over-
expressed in murine hematopoietic progenitors [36]. The disease
induced by BCL2A1a was more aggressive and had much shorter
Figure 5. Survival curves. Kaplan-Meier overall survival and disease-free survival curves for primary transplanted mice and secondary transplanted
mice (vector control or BCL2A1a): Overall survival includes deaths due to hematologic tumors and all other causes (radiation toxicity and related
premature aging), with censoring of primary animals only when euthanized and utilized for secondary transplants. Overall survival curves shown in
(A), (C), and (E) respectively correspond to primary mice, first set of secondary mice, and second set of secondary mice. The disease-free survival
curves show development of hematologic disease (leukemia/lymphoma) as assessed by autopsy and histopathology analyses of all organs. Animals
that died of non-hematologic causes were censored at their time of death. Disease-free survival curves shown in (B), (D), and (F) respectively
correspond to primary mice, first set of secondary mice, and second set of secondary mice. The number of mice constituting a group is indicated
between parenthesis, and median survivals are indicated in days. n.s. = not significant.
doi:10.1371/journal.pone.0048267.g005
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latency in secondary recipients. The phenotype was transplantable
and of primitive origin. It was interesting to note that the
phenotype was more aggressive and the latency shorter in non-
ablated secondary recipients. This initially surprising finding is
actually in accordance with the work of Sadat and colleagues [37].
Retrovirally-induced leukemias and clonal dominance in their
murine model was more rapid and frequent in sub-lethally-
irradiated as compared to irradiated recipients.
In conclusion, we determined that the over-expression of
BCL2A1a in murine hematopoietic stem and progenitor cells
can prevent apoptosis, enhance engraftment, and promote
eventual outgrowth of fully transformed leukemic cells, primarily
of the B lymphoid lineage. Our studies suggest that further
investigation of BCL2A1 as a participant in hematologic
transformation is indicated, and it adds BCL2A1 to the list of
proto-oncogenes that can be activated by insertional mutagenesis.
Figure 6. Lineage Analyses and clonality of Tumor Cells. (A) T-cell receptor b gene rearrangement. Genomic DNA isolated from bone marrow
of three primary mice diagnosed with leukemia/lymphoma (#25, 32, and 33) and expressing HA-tagged BCL2A1a were subjected to a Southern blot
analysis using a Cb2 probe able to recognize the Cb1 and Cb2 region of the T-cell receptor b gene. Germline genomic DNA should produce bands of
8.9 and 2.9 Kb when digested with HindIII, and a band of 11.1 Kb when digested with SacI. NIH3T3 cells (N) were used as a control. Ladder size is
given in base pairs. (B, C) Immunoglobulin gene rearrangements. PCRs to assess V to DJ rearrangements were performed with primers identifying the
degenerated heavy variable region (VH558 and VH7183) as forward primers and J3 (B) or J4 (C) primers recognizing J3 or J4 genes. PCRs were
performed on genomic DNA isolated from the bone marrow of control mice (MOCK#3 and vector#7), three primary mice diagnosed with leukemia/
lymphoma (#25, 32, and 33), and one secondary mouse also diagnosed with leukemia (#24-12 expressing HA-tagged BCL2A1a). Genomic DNA
obtained from BaF3 cells (B) and regular bone marrow from C57BL/6 mouse (M) were used as controls as well as a no-template control with water
(W). Ladder size is given in base pairs, and are designated by a white dot. White arrows indicate the J gene involved in the rearrangement. The
complete panel of PCRs for V to DJ and V to J rearrangements as well as germline configurations are shown in Supplemental Figure S4. (D) Southern
blot performed with a GFP probe on genomic DNA isolated from whole bone marrow cells of primary mice. Genomic DNA obtained from regular
bone marrow from C57BL/6 mouse (M) and from K562/D33 (K) harboring one copy of pRRL.PPT.SF.IRES.GFPpre/HA were respectively used as
negative and positive controls. Control mice MOCK #3 and vector #7 were also used as controls. #25, 32, 33, 28, and 26 were primary mice
diagnosed with leukemia/lymphoma. Ladder size is given in base pairs. (E) Southern blot performed with GFP probe on genomic DNA isolated from
whole bone marrow (BM), lymph node (LN), or peripheral blood (PB) cells of secondary mice. Genomic DNA obtained from BaF3 cells (B) and from
K562/AL (K) harboring two copy of GFP vector were respectively used as negative and positive controls. Plasmid pRRL.PPT.SF.IRES.GFPpre/HA-
BCL2A1a was also used as a positive control. Mice vector#7 and primary BCL2A1a#25 were used as controls. Secondary BCL2A1a#29-16, 35-18, 35-
19, and vector#20-9 mice belong to the first set of secondary transplant. Secondary BCL2A1a mouse#23-11 belongs to the second set of secondary
transplant. All secondary mice were diagnosed with lymphoma/leukemia. Ladder size is given in base pairs.
doi:10.1371/journal.pone.0048267.g006
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Supporting Information
Figure S1 Blood cell count at the time of sacrifice. Blood
cell counts at the time of sacrifice were determined and compared
by a t-test for vector control and BCL2A1a groups. (A, B, C)
respectively represent the primary mice cohort for WBC, RBC,
and platelets. (D, E, F) respectively represent the first secondary
mice cohort for WBC, RBC, and platelets. Data averages plus
standard deviations were plotted. WBC = white blood cells, RBC
= red blood cells, k/uL = thousands of cells per microliter, M/
uL = millions of cells per microliter, n.s. = not significant.
(TIF)
Figure S2 BCL2A1a Recipient Mice Development of
Lymphadenopathy and Organomegaly. (A) Representative
pictures of each group of recipient mice (#3= MOCK, #7=
vector, and #25= BCL2A1a). Arrows indicate lymph nodes
(blue), spleen (green), and liver (red). (B,C) The weights of the
spleen and liver at sacrifice were determined and compared. For
primary mice, the 3 groups were compared using one way
ANOVA test for MOCK, vector, and BCL2A1a mice. (D,E,F,G)
For secondary mice, vector and BCL2A1a mice were compared
using an unpaired t-test. (D) and (E) respectively show the weight
of liver and spleen obtained for the first set of secondary
transplanted mice. (F) and (G) respectively show the weight of
liver and spleen obtained for the second set of secondary
transplanted mice. Data averages plus standard deviations were
plotted. mg = milligrams, n.s. = not significant.
(TIF)
Figure S3 Analyses of peripheral blood and bone
marrow cells by flow cytometry at the time of
sacrifice. Peripheral blood or flushed bone marrow cells were
stained with antibodies recognizing Ly5.1 and Ly5.2 for
chimerism, as well as antibodies recognizing CD3e, B220, and
CD11b to respectively detect T-Cells, B-Cells, and granulocytes
(See Material and Methods section). (A, C, E, G) represent data
obtained for the peripheral blood of vector control mouse #7,
primary BCL2A1a mice #25 and #33, and secondary
BCL2A1a mouse #24-12. (B, D, F) represent data obtained
for the bone marrow of vector control mouse #7 and primary
BCL2A1a mice #25 and #33.
(TIF)
Figure S4 Analyses of immunoglobulin heavy variable
chain rearrangement. All PCRs were carried out on genomic
DNA isolated from bone marrow with either J3 (A) or J4 (B, C) as
reverse primers with a unique sequence. Forward primers were
used to assess germline configuration, V to DJ, or D to J
rearrangements. Germline configuration was assessed with Mu0
primer. V to DJ rearrangements were assessed with degenerated
primers that identified heavy variable regions (VH558, VH7183,
and VHQ52). D to J rearrangements were assessed with
degenerated primers DHL and DHR identifying D genes. Primers
were described by Schlissel and colleagues [28]. Mice tested and
controls are the same than for Figure 6. B = BaF3 cells, M =
regular bone marrow from C57BL/6 mouse, and W = water.
Ladder size is given in base pair and are emphasized by a white
dot. White arrows indicate the J gene involved in the rearrange-
ment. Black arrow indicates germline configuration.
(TIF)
Table S1 Analyses of lentiviral insertion sites. Mapping
of lentiviral insertion sites from the bone marrow cells of two
BCL2A1a mice (primary #25 and secondary #23-11) with
tumors, and one vector control mouse without tumor (primary
#7). Mice #7 and #25 were analyzed by LAM-PCR [38] and
mouse #23-11 was analyzed by LM-PCR [39–40].
(XLSX)
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